Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 24;108(6):1249-1255.
doi: 10.4269/ajtmh.22-0539. Print 2023 Jun 7.

Dengue and COVID-19 Co-Circulation in the Peruvian Amazon: A Population-Based Study

Affiliations

Dengue and COVID-19 Co-Circulation in the Peruvian Amazon: A Population-Based Study

Maria J Pons et al. Am J Trop Med Hyg. .

Abstract

The COVID-19 pandemic affected the main Amazon cities dramatically, with Iquitos City reporting the highest seroprevalence of anti-SARS-CoV-2 antibodies during the first COVID-19 wave worldwide. This phenomenon raised many questions about the possibility of a co-circulation of dengue and COVID-19 and its consequences. We carried out a population-based cohort study in Iquitos, Peru. We obtained a venous blood sample from a subset of 326 adults from the Iquitos COVID-19 cohort (August 13-18, 2020) to estimate the seroprevalence of anti-dengue virus (DENV) and anti-SARS-CoV-2 antibodies. We tested each serum sample for anti-DENV IgG (serotypes 1, 2, 3, and 4) and SARS-CoV-2 antibodies anti-spike IgG and IgM by ELISA. We estimated an anti-SARS-CoV-2 seroprevalence of 78.0% (95% CI, 73.0-82.0) and an anti-DENV seroprevalence of 88.0% (95% CI, 84.0-91.6), signifying a high seroprevalence of both diseases during the first wave of COVID-19 transmission in the city. The San Juan District had a lower anti-DENV antibody seroprevalence than the Belen District (prevalence ratio, 0.90; 95% CI, 0.82-0.98). However, we did not observe these differences in anti-SARS-CoV-2 antibody seroprevalence. Iquitos City presented one of the highest seroprevalence rates of anti-DENV and anti-SARS-CoV-2 antibodies worldwide, but with no correlation between their antibody levels.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
COVID-19 and dengue epidemics in Iquitos City from 2019 through 2021.
Figure 2.
Figure 2.
Seroprevalence of COVID-19, dengue, and active dengue among adults across Iquitos City overall (A) and disaggregated by age group and rural/urban area for COVID-19 seroprevalence (B) dengue seroprevalence (C), and dengue incidence (D).
Figure 3.
Figure 3.
(A) Anti-dengue IgG antibody (Abs) absorbance units by Iquitos district. Active cases of dengue are located above the solid line. (B) COVID-19 IgG Abs absorbance units by Iquitos district.

Similar articles

Cited by

References

    1. Cardona-Ospina JA. et al., 2021. Dengue and COVID-19, overlapping epidemics? An analysis from Colombia. J Med Virol 93: 522–527. - PMC - PubMed
    1. Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, Gubler DJ, 2020. Preventing dengue epidemics during the COVID-19 pandemic. Am J Trop Med Hyg 103: 570–571. - PMC - PubMed
    1. Mendenhall E, Newfield T, Tsai AC, 2022. Syndemic theory, methods, and data. Soc Sci Med 295: 114656. - PMC - PubMed
    1. Hilmy AI, Dey RK, Imad HA, Yoosuf AA, Nazeem A, Latheef AA, 2021. Coronavirus disease 2019 and dengue: two case reports. J Med Case Reports 15: 171. - PMC - PubMed
    1. Pontes RL, de Brito BB, da Silva FAF, Figueredo MS, Correia TML, Teixeira AF, Oliveira MV, de Melo FF, 2020. Coinfection by SARS-CoV-2 and dengue virus in a dual viral circulation setting. Travel Med Infect Dis 37: 101862. - PMC - PubMed

Publication types